313527-64-9

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 40925-68-6 2-amino-4-bromo-phenol 
• 150-13-0 4-amino-benzoic acid 
• 1134-36-7 2-amino-4-phenylphenol 
• 122-04-3 4-nitro-benzoyl chloride 
• 885-82-5 4-phenyl-2-nitrophenol 
• 7647-01-0 hydrogenchloride 
• 64-19-7 acetic acid 

Relevant academic research and scientific papers

Tribenzazole amine derivatives and organic electroluminescent device including the same

The present invention provides a tribenzazole amine derivative which contributes to substantial life improvement of an organic electroluminescent device by effectively absorbing a high energy external light source of an UV area and minimizing the damage of organic materials in the organic electroluminescent device. The organic electroluminescent device according to the present invention includes: a first electrode; a second electrode; an organic material layer disposed between the first electrode and the second electrode; and a capping layer disposed on the second electrode. The capping layer includes a tribenzazole amine derivative represented by chemical formula 1. In chemical formula 1, R^1, R^2 and R^3 are the same as or different from each other and are respectively and independently hydrogen and an alkyl group having 1 to 10 carbon atoms. l, n, and m are integers of 0 to 4.COPYRIGHT KIPO 2020

Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation

MicroRNAs (miRNAs) are short, non-coding RNA molecules estimated to regulate expression of a large number of protein-coding genes and are implicated in a variety of biological processes such as development, differentiation, proliferation, and cell surviva

SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS

The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.